|
1
|
Zhang X, Ng WL, Wang P, Tian L, Werner E,
Wang H, Doetsch P and Wang Y: MicroRNA-21 modulates the levels of
reactive oxygen species by targeting SOD3 and TNFα. Cancer Res.
72:4707–4713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ouyang YB, Lu Y, Yue S and Giffard RG:
miR-181 targets multiple Bcl-2 family members and influences
apoptosis and mitochondrial function in astrocytes. Mitochondrion.
12:213–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Webb PM, Purdie DM, Grover S, Jordan S,
Dick ML and Green AC: Symptoms and diagnosis of borderline, early
and advanced epithelial ovarian cancer. Gynecol Oncol. 92:232–239.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singer CF, Tea MK, Pristauz G, Hubalek M,
Rappaport C, Riedl C and Helbich T: Guideline for the prevention
and early detection of breast and ovarian cancer in high risk
patients, particularly in women from HBOC (hereditary breast and
ovarian cancer) families. Wien Klin Wochenschr. 124:334–339.
2012.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu P, Zhou L, Ke W and Li K: Clinical
significance of pAKT and CD44v6 overexpression with breast cancer.
J Cancer Res Clin Oncol. 136:1283–1292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Afify A, Purnell P and Nguyen L: Role of
CD44s and CD44v6 on human breast cancer cell adhesion, migration,
and invasion. Exp Mol Pathol. 86:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liang J, Jiang D, Griffith J, Yu S, Fan J,
Zhao X, Bucala R and Noble PW: CD44 is a negative regulator of
acute pulmonary inflammation and lipopolysaccharide-TLR signaling
in mouse macrophages. J Immunol. 178:2469–2475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsumura Y, Hanbury D, Smith J and Tarin
D: Non-invasive detection of malignancy by identification of
unusual CD44 gene activity in exfoliated cancer cells. BMJ.
308:619–624. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Zha XM, Wang R, Li XD, Xu B, Xu YJ
and Yin YM: Regulation of CD44 expression by tumor necrosis
factor-α and its potential role in breast cancer cell migration.
Biomed Pharmacother. 66:144–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagel S, Hirschmann P, Dirnhofer S,
Günthert U and Tzankov A: Coexpression of CD44 variant isoforms and
receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an
International Prognostic Index and C-MYC gene status-independent
predictor of poor outcome in diffuse large B-cell lymphomas. Exp
Hematol. 38:38–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi J, Zhou Z, Di W and Li N: Correlation
of CD44v6 expression with ovarian cancer progression and
recurrence. BMC Cancer. 13:1822013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao S, He JL, Qiu ZX, Chen NY, Luo Z,
Chen BJ and Li WM: Prognostic value of CD44 variant exon 6
expression in non-small cell lung cancer: a meta-analysis. Asian
Pac J Cancer Prev. 15:6761–6766. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jung T, Gross W and Zöller M: CD44v6
coordinates tumor matrix-triggered motility and apoptosis
resistance. J Biol Chem. 286:15862–15874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Xiao L, Luo CH, Zhou H, Zeng L,
Zhong J, Tang Y, Zhao XH, Zhao M and Zhang Y: CD44v6 promotes
β-catenin and TGF-β expression, inducing aggression in ovarian
cancer cells. Mol Med Rep. 11:3505–3510. 2015.PubMed/NCBI
|
|
15
|
Misra S, Heldin P, Hascall VC, Karamanos
NK, Skandalis SS, Markwald RR and Ghatak S: Hyaluronan-CD44
interactions as potential targets for cancer therapy. FEBS J.
278:1429–1443. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heider KH, Kuthan H, Stehle G and Munzert
G: CD44v6: a target for antibody-based cancer therapy. Cancer
Immunol Immunother. 53:567–579. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marhaba R and Zöller M: CD44 in cancer
progression: adhesion, migration and growth regulation. J Mol
Histol. 35:211–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spiegelberg D, Kuku G, Selvaraju R and
Nestor M: Characterization of CD44 variant expression in head and
neck squamous cell carcinomas. Tumour Biol. 35:2053–2062. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ponta H, Sherman L and Herrlich PA: CD44:
from adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rassouli FB, Matin MM, Bahrami AR,
Ghaffarzadegan K, Cheshomi H, Lari S, Memar B and Kan MS:
Evaluating stem and cancerous biomarkers in CD15+CD44+ KYSE30
cells. Tumour Biol. 34:2909–2920. 2013. View Article : Google Scholar : PubMed/NCBI
|
